Posted by Michael Wonder on 11 Oct 2016
FDA grants priority review to Roche's Lucentis for mCNV
11 October 2016 - The U.S. FDA has granted priority review for Roche drug Lucentis (ranibizumab) for treating myopic choroidal neovascularization, the Swiss drug maker said on Tuesday.
The ailment is a complication of severe near-sightedness that can lead to blindness, it added in a statement.
